

Untitled

AAE19112

ID AAE19112 standard; protein; 117 AA.

XX

AC AAE19112;

XX

DT 21-MAY-2002 (first entry)

XX

DE Human Nkp46D2 (isoform b) protein.

XX

KW Human; natural killer cell activating protein; Nkp46; therapy; virucide; viral infection; natural killer cell; NK; Nkp44; imaging agent; cancer; detection; carcinoma; melanoma; lymphoma; sarcoma; cytostatic.

XX

OS Homo sapiens.

XX

PN WC200208287- A2.

XX

PD 31-JAN-2002.

XX

PF 19-JUL-2001; 2001WC-IL000664.

XX

PR 20-JUL-2000; 2000IL-00137419.

XX

PA (YISS) YISSUM RES DEV CO HEBREW UNI V JERUSALEM

PA (UYNE) UNI V BEN-GURION NEGEV.

XX

PI Mandelboim Q, Porgador A;

XX

DR VPI; 2002-195870/25.

DR N-PSDB; AAD30469.

XX

PT New targeting complex capable of targeting an active substance to a target cell, comprising a target recognition segment and an active segment, useful for treating pathologies associated with viral infections or cancer.

PT

XX Claim 4; Page 111-112; 113pp; English.

PS

XX

CC The invention relates to compositions and methods for the treatment and detection of a variety of viral infections, by using complex agents comprising the natural killer (NK) cells activating proteins, Nkp46 and Nkp44 and functional fragments thereof, linked to therapeutic or imaging agents. The complex is useful for treating pathologies associated with viral infections (e.g. infections caused by influenza virus, HIV, Epstein-Barr virus, cytomegalovirus, vaccinia virus, EQM, M/M or herpes virus) and cancer (e.g. carcinomas, melanomas, lymphomas and sarcomas), and for the imaging and monitoring of cancer. The complex may also be used to detect the presence of abnormal cells in a sample. The antibodies can be used to qualitatively or quantitatively detect the ligand for the complex. The present sequence is human Nkp46 (isoform b) domain 2

XX

SQ Sequence 117 AA;

Query Match 100.0% Score 102; DB 5; Length 117;

Best Local Similarity 100.0% Pred. No. 6.2e-09;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Gy 1 FLLLLKEGRSSHVQGYGVQ 20

Db 33 FLLLLKEGRSSHVQGYGVQ 52

|||||

Untitled

AAE19109

ID AAE19109 standard; protein; 135 AA.

XX

AC AAE19109;

XX

DT 21-MAY-2002 (first entry)

XX

DE Human Nkp30 protein.

XX

KW Human; natural killer cell activating protein; Nkp46; therapy; virucide;
KW viral infection; natural killer cell; NK; Nkp44; imaging agent; cancer;
KW detection; carcinoma; melanoma; lymphoma; sarcoma; cytostatic; Nkp30.

XX

OS Homo sapiens.

XX

PN WC200208287-A2.

XX

PD 31-JAN-2002.

XX

PF 19-JUL-2001; 2001WCIL000664.

XX

PR 20-JUL-2000; 2000IL-00137419.

XX

PA (YISS) YISSUM RES DEV CO HEBREW UNI V JERUSALEM

XX

PA (UYNE) UNI V BEN-GURION NEGEV.

XX

PI Mandelboim O, Porgador A;

XX

DR VPI; 2002-195870/25.

XX

DR N-PSDB; AAD30466.

XX

PT New targeting complex capable of targeting an active substance to a
PT target cell, comprising a target recognition segment and an active
PT segment, useful for treating pathologies associated with viral infections
PT or cancer.

XX

PS Example 1; Page 108; 113pp; English.

XX

CC The invention relates to compositions and methods for the treatment and
CC detection of a variety of viral infections, by using complex agents
CC comprising the natural killer (NK) cells activating proteins, Nkp46 and
CC Nkp44 and functional fragments thereof, linked to therapeutic or imaging
CC agents. The complex is useful for treating pathologies associated with
CC viral infections (e.g. infections caused by influenza virus, HIV, Epstein
CC -Barr virus, cytomegalovirus, vaccinia virus, EQW, M/M or herpes virus)
CC and cancer (e.g. carcinomas, melanomas, lymphomas and sarcomas), and for
CC the imaging and monitoring of cancer. The complex may also be used to
CC detect the presence of abnormal cells in a sample. The antibodies can be
CC used to qualitatively or quantitatively detect the ligand for the
CC complex. The present sequence is human Nkp30 protein

XX

SQ Sequence 135 AA;

Query Match 100.0% Score 143; DB 5; Length 135;

Best Local Similarity 100.0% Pred. No. 1.5e-13;

Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RDEVVPGKEVRNGTPEFRGLAPLASSR 28

Db 57 RDEVVPGKEVRNGTPEFRGLAPLASSR 84

AAE19109

ID AAE19109 standard; protein; 135 AA.

XX

AC AAE19109;

XX

DT 21-MAY-2002 (first entry)

XX

DE Human Nkp30 protein.

XX

KW Human; natural killer cell activating protein; Nkp46; therapy; virucide;
KW viral infection; natural killer cell; NK; Nkp44; imaging agent; cancer;
KW detection; carcinoma; melanoma; lymphoma; sarcoma; cytostatic; Nkp30.

XX

OS Homo sapiens.

XX

PN WC200208287-A2.

XX

PD 31-JAN-2002.

XX

PF 19-JUL-2001; 2001WD-IL000664.

XX

PR 20-JUL-2000; 2000IL-00137419.

XX

PA (YISS) YISSUM RES DEV CO HEBREW UNI V JERUSALEM
PA (UYNE) UNI V BEN-GURION NEGEV.

XX

PI Mandelboim O, Porgador A;

XX

DR VPI: 2002-195870/25.

DR N-PSDB; AAD30466.

XX

PT New targeting complex capable of targeting an active substance to a
PT target cell, comprising a target recognition segment and an active
PT segment, useful for treating pathologies associated with viral infections
PT or cancer.

XX

PS Example 1; Page 108; 113pp; English.

XX

CC The invention relates to compositions and methods for the treatment and
CC detection of a variety of viral infections, by using complex agents
CC comprising the natural killer (NK) cells activating proteins, Nkp46 and
CC Nkp44 and functional fragments thereof, linked to therapeutic or imaging
CC agents. The complex is useful for treating pathologies associated with
CC viral infections (e.g. infections caused by influenza virus, HIV, Epstein
CC -Barr virus, cytomegalovirus, vaccinia virus, ECV, M/M or herpes virus)
CC and cancer (e.g. carcinomas, melanomas, lymphomas and sarcomas), and for
CC the imaging and monitoring of cancer. The complex may also be used to
CC detect the presence of abnormal cells in a sample. The antibodies can be
CC used to qualitatively or quantitatively detect the ligand for the
CC complex. The present sequence is human Nkp30 protein

XX

SQ Sequence 135 AA;

Query Match 100.0% Score 107; DB 5; Length 135;
Best Local Similarity 100.0% Pred. No. 1.4e-08;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RDEVVPGKEVRNGTPEFRGR 20
Db 57 RDEVVPGKEVRNGTPEFRGR 76

Untitled

AAE19105

ID AAE19105 standard; protein; 190 AA.

XX

AC AAE19105;

XX

DT 21-MAY-2002 (first entry)

XX

DE Human Nkp44 protein.

XX

KW Human; natural killer cell activating protein; Nkp46; therapy; virucide;
KW viral infection; natural killer cell; NK; Nkp44; imaging agent; cancer;
KW detection; carcinoma; melanoma; lymphoma; sarcoma; cytostatic.

XX

OS Homo sapiens.

XX

PN WC200208287-A2.

XX

PD 31-JAN-2002.

XX

PF 19-JUL-2001; 2001WD-IL000664.

XX

PR 20-JUL-2000; 2000IL-00137419.

XX

PA (YISS) YISSUM RES DEV CO HEBREW UNI V JERUSALEM

XX

PA (UYNE) UNIV BEN-GURION NEGEV.

XX

PI Mandelboim O, Porgador A;

XX

DR VPI: 2002-195870/25.

XX

DR N-PSDB; AAD19105.

XX

PT New targeting complex capable of targeting an active substance to a
PT target cell, comprising a target recognition segment and an active
PT segment, useful for treating pathologies associated with viral infections
PT or cancer.

XX

PS Claim 6; Page 101; 113pp; English.

XX

CC The invention relates to compositions and methods for the treatment and
CC detection of a variety of viral infections, by using complex agents
CC comprising the natural killer (NK) cells activating proteins, Nkp46 and
CC Nkp44 and functional fragments thereof, linked to therapeutic or imaging
CC agents. The complex is useful for treating pathologies associated with
CC viral infections (e.g. infections caused by influenza virus, HIV, Epstein
CC -Barr virus, cytomegalovirus, vaccinia virus, ECMV, MCM or herpes virus)
CC and cancer (e.g. carcinomas, melanomas, lymphomas and sarcomas), and for
CC the imaging and monitoring of cancer. The complex may also be used to
CC detect the presence of abnormal cells in a sample. The antibodies can be
CC used to qualitatively or quantitatively detect the ligand for the
CC complex. The present sequence is human Nkp44 protein

XX

SQ Sequence 190 AA;

Query Match 100.0% Score 127; DB 5; Length 190;

Best Local Similarity 100.0% Pred. No. 6.5e-12;

Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KKGWCKEASALVCI FLVTSSKPRT 24

Db 51 KKGWCKEASALVCI FLVTSSKPRT 74

Untitled

.....

..